Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Evaluation of murine leukemia virus infection as a model for thrombocytopenia of HIV/AIDS: mechanism of thrombocytopenia and modulation of thrombocytopenia by thrombopoietin.
AIDS Res Hum Retroviruses. 1995 Jul;11(7):837-42. Unique Identifier : AIDSLINE MED/96053847 Sullivan PS; McDonald TP; Department of Animal Science, College of Veterinary Medicine,; University of Tennessee, Knoxville 37901, USA.
Abstract:
Infection of mice with the murine leukemia virus (LP-BM5) was evaluated as a model for the thrombocytopenia of HIV/AIDS. Percent 35S incorporation into platelets, platelet size, platelet count, platelet-associated immunoglobulins (PAIgG), and megakaryocyte size and number were evaluated over a period of 3-9 weeks postinfection (PI). Thrombopoietin from human embryonic kidney cells was administered to mice 9 weeks PI, and similar indices of platelet production were measured 2, 3, and 4 days after treatment with a biological preparation of thrombopoietin (thrombocytopoiesis-stimulating factor, or TSF). Platelet counts decreased in a time-dependent fashion (p = 0.0006) following infection, reaching a nadir at 8 weeks PI (82% of control values). Percent 35S incorporation into platelets also decreased over the 9-week period (p = 0.0001), falling to 63% of control values by week 9. Additionally, platelet volume increased in a linear fashion (p = 0.01), rising to 105% of control values by week 9. No changes in PAIgG were noted over the 9-week period. Megakaryocyte numbers in the femoral marrow were decreased at 8 weeks PI (p = 0.02, 78% of control values), while increased mean megakaryocyte size (p = 0.007, 116% of controls) was noted in the same animals. Increased numbers of naked megakaryocyte nuclei were observed at 3 weeks PI (p < 0.05, 208% of control values). Administration of 2 U/mouse of a highly purified preparation of TSF to virus-infected, thrombocytopenic mice resulted in increased thrombocytopoiesis, as compared to human serum albumin-treated, virus-infected controls.(ABSTRACT TRUNCATED AT 250 WORDS)
Keywords: Acquired Immunodeficiency Syndrome/*BLOOD Animal Bone Marrow/CYTOLOGY/PATHOLOGY Cell Line Disease Models, Animal Hematopoietic Stem Cells/CYTOLOGY/PATHOLOGY Human *HIV HIV Infections/*BLOOD Kidney *Leukemia Viruses, Murine Male Megakaryocytes/CYTOLOGY/PATHOLOGY Mice Mice, Inbred C57BL Platelet Count Regression Analysis Retroviridae Infections/*BLOOD Support, U.S. Gov't, P.H.S. Thrombocytopenia/*ETIOLOGY/PATHOLOGY/*THERAPY Thrombopoietin/*THERAPEUTIC USE Time Factors Tumor Virus Infections/*BLOOD JOURNAL ARTICLE
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
